Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery


ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges

Author(s): Filomena de Nigris, Concetta Schiano, Teresa Infante and Claudio Napoli

Volume 7, Issue 3, 2012

Page: [251 - 264] Pages: 14

DOI: 10.2174/157489212801820039

Price: $65


CXCL12, also known as SDF-1, is the single natural ligand for chemokine receptors CXCR4 and CXCR7. CXCL12 has angiogenic properties in normal endothelial tissue and is involved in the outgrowth and metastasis of CXCR4 expressing tumors. Recent investigations have indicated that CXCL12 levels increase after chemo- and anti- VEGF therapy, favouring recurrences. The blockade of CXCL12/CXCR4 axis has emerged as a potential additional or alternative target for neo-adjuvant treatments. We have reviewed recent patent applications between 2008 and 2011 in tumor angiogenesis and the most clinical data supporting the potential use of anti-CXCR4 agents in this field. Among these, AMD3100, also known as Plerixaform (Mozobil® by Genzyme), is approved for stem cell mobilisation in patients with leukaemia, while BKT140 (Emory University), POL6326 (Polyphor Ag) and TG-0054 (ChemoCentryx) are currently in clinical trials in combination with chemotherapy for multiple myeloma and leukaemia. The aptamer Nox-A12 (Noxxon) is in trials for chronic lymphatic leukaemia treatment. MSX-122 (Metastatix) is in Phase I trials for solid tumor treatment, while CXCR7-specific inhibitor CCX2066 (ChemoCentryx) is still in preclinical studies. We have also considered other strategies, such RNA interference and miRNA, which could be tested for solid tumor adjuvant therapy.

Keywords: Angiogenesis, cancer, CXCL12, CXCR4, metastasis, vasculogenesis, CCX2066 (ChemoCentryx), multiple myeloma, leukaemia, chronic lymphatic leukaemia treatment

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy